ENA Respiratory Revenue and Competitors

Melbourne, au

Location

N/A

Total Funding

Employee Data

  • ENA Respiratory has 8 Employees.(i)
  • ENA Respiratory grew their employee count by 14% last year.

ENA Respiratory's People

NameTitleEmail/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
N/A650%N/AN/A
#2
N/A10242%N/AN/A
#3
N/A9630%N/AN/A
#4
N/A814%N/AN/A
Add Company

What Is ENA Respiratory?

ENA Respiratory is a clinical-stage pharmaceutical company developing INNA-051, an intranasal innate immune modulator for the prevention of complications resulting from respiratory viral infections in at-risk populations, including older adults, those with co-morbidities (COPD, asthma, diabetes, and cardiovascular disease) and individuals with occupational risk. The ENA team has a long history of successful drug development in respiratory diseases and seeks to leverage this expertise to meet the considerable unmet need that still exists for these vulnerable populations.\n\nENA Respiratory has partnered with the COPD Foundation to enable and optimize patient-centered clinical development of INNA-051 in COPD. In 2022, it joined BLUE KNIGHT™, a joint initiative between Johnson & Johnson Innovation and BARDA designed to accelerate development of potential solutions for future pandemics. In 2023, the company was awarded a $8.18 million contract from the U.S. Department of Defense to support the continued development of INNA-051.\n \n\n \n \n Show more\n \n\n \n\n\n \n \n Show less

keywords:N/A

N/A

Total Funding

8

Number of Employees

N/A

Revenue (est)

14%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$0.6M8-11%N/A
#2
$0.6M8N/AN/A
#3
$0.6M80%N/A
#4
$0.5M8-11%N/A
#5
$0.6M80%N/A